Key facts
- Diagnoly’s last known valuation is $17.0M (Apr 2025).
- It has raised $6.8M; the latest was Seed Round ($6.0M) in Apr 2025.
- Notable investors include MassChallenge, Newfund Management, XAnge, Angelor, La Synapse — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Diagnoly
- ·The full record, as it builds
Funding rounds
No funding rounds for Diagnoly are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Diagnoly
Developer a medical device designed for clinicians to perform ultrasound imaging of human fetuses. The company's tools use artificial intelligence to define fetal biometric key parameters that help in fetal ultrasound examination, enabling clinicians to detect pregnancy complication factors and fetal abnormalities.
- Sector
- Healthcare
- HQ
- Lyon, France
- Founded
- 2020
- Employees
- 23
- Website
- diagnoly.com/
- Ownership
- Privately Held (backing)
Diagnoly doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Diagnoly shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Diagnoly in its N-PORT filings yet. We sweep new filings monthly.